1. Home
  2. AROW vs DBVT Comparison

AROW vs DBVT Comparison

Compare AROW & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arrow Financial Corporation

AROW

Arrow Financial Corporation

HOLD

Current Price

$30.00

Market Cap

442.9M

Sector

Finance

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$13.02

Market Cap

464.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AROW
DBVT
Founded
1851
2002
Country
United States
France
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
442.9M
464.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AROW
DBVT
Price
$30.00
$13.02
Analyst Decision
Hold
Buy
Analyst Count
1
5
Target Price
$28.00
$15.85
AVG Volume (30 Days)
57.3K
118.6K
Earning Date
10-30-2025
10-28-2025
Dividend Yield
3.89%
N/A
EPS Growth
5.41
N/A
EPS
2.07
N/A
Revenue
$146,817,000.00
$5,502,000.00
Revenue This Year
$25.16
$1,743.46
Revenue Next Year
$9.99
$1,045.66
P/E Ratio
$14.43
N/A
Revenue Growth
7.84
N/A
52 Week Low
$22.72
$2.70
52 Week High
$33.56
$18.00

Technical Indicators

Market Signals
Indicator
AROW
DBVT
Relative Strength Index (RSI) 52.49 43.06
Support Level $28.98 $12.70
Resistance Level $30.96 $14.68
Average True Range (ATR) 1.03 0.93
MACD -0.06 -0.14
Stochastic Oscillator 36.70 21.86

Price Performance

Historical Comparison
AROW
DBVT

About AROW Arrow Financial Corporation

Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of company's revenue is interest income, fees, commission earned through its subsidiaries.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: